| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6384020 | TEVA WOMENS | Rapid immediate release oral dosage form |
Jul, 2020
(3 years ago) | |
|
US6384020 (Pediatric) | TEVA WOMENS | Rapid immediate release oral dosage form |
Jan, 2021
(3 years ago) | |
Adderall 12.5 is owned by Teva Womens.
Adderall 12.5 contains Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate.
Adderall 12.5 has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Adderall 12.5 are:
- US6384020
- US6384020*PED
Adderall 12.5 was authorised for market use on 13 February, 1996.
Adderall 12.5 is available in tablet;oral dosage forms.
The generics of Adderall 12.5 are possible to be released after 06 January, 2021.
Market Authorisation Date: 13 February, 1996
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of ADDERALL 12.5 before it's drug patent expiration?
More Information on Dosage
ADDERALL 12.5 family patents
